<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04229680</url>
  </required_header>
  <id_info>
    <org_study_id>1423170</org_study_id>
    <nct_id>NCT04229680</nct_id>
  </id_info>
  <brief_title>The Salty Gut: Effects of High Dietary Salt Intake on the Gut Microbiota</brief_title>
  <official_title>The Salty Gut: Effects of High Dietary Salt Intake on the Gut Microbiota</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Delaware</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Delaware</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gut microbiota has a role in cardiovascular disease and recent findings in rodents show
      dietary salt can negatively alter gut microbiota composition. High salt intake is a risk
      factor for cardiovascular disease. Americans consume dietary salt in excess of Dietary
      Guidelines and American Heart Association recommendations. The objective of this project is
      to investigate the influence of high dietary salt consumption on the gut microbiota
      composition in men and women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gut microbiota composition and function has an important role in host physiology. In general,
      gut microbial diversity is positively correlated with health status. Recent evidence confirms
      the role of gut dysbiosis in cardiovascular disease. Americans consume 50% more salt than the
      amount recommended by the Dietary Guidelines and 130% more than recommended by the American
      Heart Association. Excess salt intake is considered a modifiable risk factor for
      cardiovascular disease. Changes in the gut microbiota composition followed by immune system
      activation is reported with high salt intake in animals. In particular, abundance of
      proinflammatory T helper 17 (Th17) cells increases with excess salt consumption. In contrast,
      T regulatory (Treg) cells oppose Th17 cell action and may aid in reducing inflammation
      associated with high salt intake, a hypothesis that has not yet been tested in humans. Only
      one preliminary study assessed changes in gut bacterial composition with high salt intake in
      humans, when only men were recruited. The study also found an increase in Th17 cell
      abundance. Thus, the objective of this study is to investigate the influence of high salt
      intake on the gut microbiota diversity and Th17 and Treg cell abundance in men and women.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>All participants will complete each arm.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Gut microbiota diversity</measure>
    <time_frame>On day 10</time_frame>
    <description>The difference in gut microbiota diversity between the two arms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T cell profile</measure>
    <time_frame>On day 10</time_frame>
    <description>The difference in T regulatory and T helper 17 cells between each arm.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Cardiovascular Risk Factor</condition>
  <arm_group>
    <arm_group_label>High Salt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be counseled to consume a diet with 2,300 mg/d sodium which they will supplement with pills containing salt to achieve an intake of 6,900 mg/d sodium.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recommended Salt</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be counseled to consume a diet with 2,300 mg/d sodium which they will supplement with placebo pills.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High Salt</intervention_name>
    <description>Consumption of pills containing table salt for 10 days.</description>
    <arm_group_label>High Salt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Recommended Salt</intervention_name>
    <description>Consumption of pills containing dextrose for 10 days.</description>
    <arm_group_label>Recommended Salt</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy

          -  normal blood pressure

        Exclusion Criteria:

          -  hypertension

          -  cardiovascular disease

          -  renal disease

          -  diabetes

          -  cancer

          -  current use of anti-inflammatory agents, glucocorticoids or other immune regulating
             medications, or certain anti-depressants

          -  history of intestinal surgery

          -  inflammatory bowel disease, celiac disease, lactose intolerance, chronic pancreatitis
             or other malabsorption disorder

          -  antibiotic use in the past 3 months

          -  prebiotic, probiotic, or antioxidant supplementation in the past 3 months

          -  â‰¥10 lbs weight gain or loss in the past 6 months

          -  use of tobacco products

          -  highly trained endurance athletes

          -  current pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shannon L Lennon, PhD, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Delaware</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katarina Smiljanec, MS</last_name>
    <phone>5405531230</phone>
    <email>ksmilja@udel.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shannon L Lennon, PhD, RD</last_name>
    <phone>3023824291</phone>
    <email>slennon@udel.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Delaware</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19716</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liza Walker, BS</last_name>
      <phone>302-831-3181</phone>
      <email>lizaj@udel.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shannon L Lennon, PhD, RD</last_name>
      <phone>3028312798</phone>
      <email>slennon@udel.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dietary sodium</keyword>
  <keyword>Gut microbiota</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

